Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 918  

 
   Table of Contents      
ORIGINAL ARTICLE
Year : 2016  |  Volume : 15  |  Issue : 2  |  Page : 109-113

Correlation between transient ischemic dilation index and endothelin-1 level in patients with Type 2 diabetes mellitus


Department of Nuclear Medicine and Molecular Imaging, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia

Date of Web Publication3-Mar-2016

Correspondence Address:
Achmad Hussein Sundawa Kartamihardja
Department of Nuclear Medicine and Molecular Imaging, Dr. Hasan Sadikin General Hospital, Bandung
Indonesia
Login to access the Email id


DOI: 10.4103/1450-1147.167576

PMID: 27134561

Rights and Permissions
   Abstract 

Transient ischemic dilation (TID) is a sensitive and specific marker for detecting the severity and extent of coronary artery disease (CAD), which is closely associated with endothelial dysfunction. TID can be observed on stress-rest myocardial perfusion scan (MPS) due to subendocardial hypoperfusion. Hyperglycemia in type 2 diabetes mellitus (T2DM) could lead to micro- and macrovascular complications and begins with endothelial dysfunction. Endothelin-1 (ET-1), a potent vasocontrictor, increases in endothelial dysfunction. The aim of this study was to examine the correlation between TID index and ET​​-1 levels in T2DM patients without any sign or symptom of cardiovascular complication. An analytic-correlational cross-sectional study was done on T2DM patients who met the inclusion criteria and agreed to participate by signing an informed consent form. The TID index was calculated automatically using standard software provided by the gamma camera GE-Infinia. Stress-rest MPS was done using technetium-99m ( 99m Tc)-tetrofosmin and a pharmacological stress test using adenosine. The ET-1 level was determined by radioimmunoassay. Data distribution was analyzed using the Shapiro-Wilk normality test. The Mann-Whitney test was used to compare the average difference of the variables and Spearman's rank for correlation analysis. A total of 47 subjects consisting of 24 (51%) males and 23 (49%) females were included in this study. The age range was 37-74 years (54.3 ± 8.4). The TID index range was 0.86-1.26 (median = 1.12) and abnormal TID index was found in 23/47 (49%) subjects. ET-1 levels range 8.02-17.91 pg/mL (median = 11.08). The results showed no significant differences in age, ET-1 levels, and TID index based on age and sex (P > 0.05). There was a significant positive correlation between TID index and ET-1 level with r = 0.7 and P < 0.001. There was a positive correlation between TID index and ET-1 plasma level in patients with T2DM.

Keywords: Endothelial dysfunction, endothelin-1, transient ischemic dilation index, type 2 diabetes mellitus


How to cite this article:
Kartamihardja AH. Correlation between transient ischemic dilation index and endothelin-1 level in patients with Type 2 diabetes mellitus. World J Nucl Med 2016;15:109-13

How to cite this URL:
Kartamihardja AH. Correlation between transient ischemic dilation index and endothelin-1 level in patients with Type 2 diabetes mellitus. World J Nucl Med [serial online] 2016 [cited 2020 Jan 28];15:109-13. Available from: http://www.wjnm.org/text.asp?2016/15/2/109/167576


   Introduction Top


Transient ischemic dilation (TID) with perfusion defect observed on myocardial perfusion scan (MPS) is a highly sensitive and specific marker for the severity and extent of cardiovascular disease and an independent and powerful predictor for cardiac event. [1],[2],[3],[4],[5] TID could be found due to decrease of blood supply to the subendocardium as a response to cardiac stress and normal at rest. Some studies have shown that there was no difference in left ventricular wall thickness anatomically during the cardiac stress test and during rest in patients with positive TID. [6],[7],[8],[9]

TID is often found in type 2 diabetes mellitus (T2DM) patients with asymptomatic cardiovascular complications. [3],[5],[10],[11]

Cardiac macro and microvascular involved in long-term complications in a T2DM patient begin with endothelial dysfunction triggered by hyperglycemia.

Endothelial dysfunction can be found to be both macro- and microvascular, which leads to an imbalance between vasodilation and vasoconstriction capability in homeostasis regulation. [12],[13],[14],[15] Endothelin-1 (ET-1) plasma level, a potent vasoconstrictor, increases, while nitric oxide (NO), a vasodilator substance, decreases in endothelial dysfunction. The vasoconstrictive effect of ET-1 is more prominent on microvascular including subendocardial compared to macrovascular. Increase in ET-1 represents an endothelial dysfunction. [16]

Ischemic or myocardial infarction complications can develop in T2DM patients, but some of them are without clinical signs or symptoms. The prevalence of myocardial ischemia was found to be hidden in 15-22% of T2DM patients. Diffuse ischemia complications involving subendocardial could be observed in T2DM patients with microvascular disorder. [3],[17],[11]

The aim of this study was to examine the correlation between TID index and ET-1 plasma levels in T2DM patients without any sign or symptom of cardiovascular complication.


   Materials and Methods Top


This study was of a prospective, analytic-correlational, cross-sectional design and was made to examine the correlation between TID index and ET-1 plasma levels in patients with T2DM. The study was conducted at the Department of Nuclear Medicine and Molecular Imaging from August 2013 to June 2014 following approval from the local Research Ethics Committee of Health.

Subjects were uncontrolled T2DM patients [based on glycated hemoglobin (HbA1c) levels] who agree to participate, and informed consent was taken from all. Subjects with a history of coronary heart disease, with stage 1 hypertension or higher based on the Seventh Joint National Committee on Prevention (JNC-7) criteria, having abnormal electrocardiogram (ECG), and having contraindications to adenosine and MPS study were excluded from the study. Subjects who met the inclusion criteria but whose MPS revealed segmental perfusion defect were also excluded.

Adenosine was used as a cardiac pharmacologic stress-test agent with a dose of 140 mcg/kg/min, and monitoring was done using 12-lead ECG. The infusion of adenosine was stopped when it reached the maximum dose, when ECG abnormalities arose, or when side effects of adenosine developed. [18]

MPS was done with the single-photon emission computed tomography (SPECT)-gated technique using a dual-headed gamma camera SPECT/CT (GE Infinia Hawkeye, GE Healthcare, New York,U.S.A) with a low-energy and high-resolution (LEHR) collimator. The imaging protocol including an energy setting at 140 KeV and 15% window width. A total of 30 image projections were collected on a 64 × 64 matrix size for 30 s/frame from the point of view right anterior oblique (RAO) 35° to left posterior oblique (LPO) 215°. Each subject underwent stress/rest gated SPECT MPS using 1-day protocol with 3-4 h interval. Technetium-99m ( 99m Tc)-tetrofosmin was used as a radiopharmaceutical with a dose of 290-370 MBq for stress imaging and 550-740 MBq for rest imaging.

The interpretation of MPS was based on the distribution of 99m Tc-tetrofosmin in the myocardium. The uptake of 99m Tc-tetrofosmin in the myocardium greater than 70% of the maximum and homogenous distribution in both stress and resting were considered to be normal. Nonhomogenous myocardial tracer uptake and less than 70% maximum uptake were considered to be abnormal (perfusion defects). [19]

The TID index was determined by using standard software available in data processing (Emory Cardiac Toolbox (ECTb tm ), Emory University, Atlanta, USA). TID index was considered to be abnormal if >1.12. [6],[20] ET-1 plasma levels in pg/mL unit were determined by using radioimmunoassay techniques.

Statistical analyses were used to examine the correlation between TID index and ET-1 plasma. The test was considered significant if the P value was less than 0.05.


   Results Top


A total of 47 subjects who met the inclusion criteria were included in this study, consisting of 24 (51%) males and 23 (49%) females. The ages ranged 37-74 years (mean: 54.3 ± 8.4 years). There was no significant difference between the proportions of males and females (P = 0.133). Values of HbA1c ranged 6.0-12.8% (mean: 8.1 ± 1.7%). The average and standard deviation (SD) of ET-1 plasma level and TID index were 10.97 (1.74) pg/mL and 1.11 (0.09), respectively. A median of ET-1 plasma level was 10.91 pg/mL and of TID index was 1.12. Abnormal TID index was found in 23/47 (49%) subjects. The Shapiro-Wilk test showed that the data obtained were not normally distributed, with P value for age 0.797, HbA1c 0.003, ET-1 plasma level 0.004, and TID index 0.037 [Table 1].
Table 1: Characteristic subject


Click here to view


As the data were not normally distributed, the Mann-Whitney test was applied to compare the differences based on sex. [Table 2] showed no significant difference on the TID index based on sex and age groups, with P values of 0.765 and 0.381, respectively. The Spearman rank test showed a significant positive correlation between ET-1 plasma level and TID index in T2DM patients with a correlation coeficient (r) = 0.7 and P < 0.001 [Table 3]. This means that TID index increases with increase of ET-1 plasma level due to endothelial dysfunction [Figure 1].
Figure 1: Correlation between ET-1 level and TID index

Click here to view
Table 2: TID index based on sex and cage


Click here to view
Table 3: Correlation between ET-1 level and TID index


Click here to view



   Discussion Top


In this study MPS was done using 99m Tc-tetrofosmin as the preparation of this radiopharmaceutical is simple and the final results were not significantly different compared to thallium-201 ( 201 TI). Adenosine was chosen for the pharmaceutical cardiac stress test due to its short duration of action. The side effects of adenosine disappear within 10 s after the discontinuation of adenosine infusion. [18] Adenosine increases myocardial perfusion by 3.5-4 times through the normal coronary artery. [21] Less dilation response to adenosin can be observed in the abnormal compared to the normal coronary artery as well as blood flow to the myocardium. This condition leads to nonhomogenous distribution of 99m Tc-tetrofosmin in the myocardium. Myocardial perfusion through the abnormal coronary artery that is less than normal is known as "steal phenomenon." [22] There was no significant side effect of adenosine observed in this study.

TID is used as a term for temporary pseudodilation involving subendocardial during cardiac stress. [6],[10],[16],[23] It was introduced for the first time by Stolzenberg in 1980. [7],[24],[25],[26] Several theories were put forward to explain the mechanism of TID, but many experts believe that TID develops due to subendocardial hypoperfusion during cardiac stress. Perfusion to the subendocardium decreases during cardiac stress, leading to the decrease of tracer uptake in the subendocardium in patients with CAD. [9],[24],[26],[27] Subendocardial hypoperfusion as a basic mechanism of TID is supported by the fact that the end-diastolic volume and left ventricular ejection fraction were not significantly different between stress and rest. [8],[24],[28],[29]

Myocardial perfusion depends on the coronary artery and its branches. The functions of the endothelium are to maintain blood supply and homeostasis in the body through maintaining the balance between vasodilation and vasocontraction. Increased levels of blood sugar in patients with T2DM can lead to endothelial disfunction. One of the important markers of endothelial dysfunction is the increase in ET-1 plasma levels, a potent vasoconstrictor. An increased ET-1 plasma level will disturb the balance between vasoconstriction and vasodilation. Increased vasoconstriction will decrease blood supply, including that to the subendocardial. [19]

In this study we found that the range of the TID index was 0.86-1.26. Based on TID index 1.12 as the cut-off value, 23 (49%) out of 47 subjects were found with abnormal TID index values. Kakhki (2007) found about 8-37% of MPS studies were associated with an abnormal TID index, [2] while Hung et al., found 26% abnormal TID index in a pharmacological stress-redistribution MPS study using 201 TI-chloride. [23],[24],[30] These differences in results could be due to the difference in radiopharmaceuticals used. [7] Hung et al. used a single injection of 201 TI-chloride, and this study used a reinjection of 99m Tc-tetrofosmin. [28]

Myocardial blood flow depends on the condition of the blood vessels, which is influenced by the ability of blood vessels to maintain the balance between vasodilation and vasocontriction. The endothelium has an important role in the regulation of blood supply and homeostasis. Endothelial response to any physical stimulus as well as chemical by releasing vasodilator and vasoconstrictor substances in order to maintain homeostasis. [12],[13],[31] ET-1 plasma levels increase in endothelial dysfunction. ET-1 is a peptide with 21 amino acids acting as autocrine. The role of ET-1 as a potent vasoconstrictor to the vascular smooth muscle was first discussed by Yanagisawa et al. in 1988. [12],[32] ET-1 leads to vasoconstriction, increases arterial tone, and controls blood pressure. [12],[31],[32],[33]

In this study the range of ET-1 levels in T2DM patients without cardiovascular complication was 8.02-17.91 pg/mL (mean = 11.48 and SD = 2.19 pg/mL). These results was not much different compared to the results from other studies. Perfetto et al. found that the mean and SD of ET-1 plasma level was 6.8 ± 2.8 pg/mL, [34] Gursel et al. found 10.46 ± 1.24 pmol/L, [13] and Schanze et al. found 11.32 ± 6.76 pg/mL. [35]

In this study, there was no correlation found between ET-1 plasma level and age. This result was similiar to that of the study done by Schneider. A different study showed a good correlation betwen ET-1 and age in type 1 diabetes mellitus (T1DM) patients. This difference may be due to differences in the duration of hyperglycemia. This hypothesis is supported by a study done by Haak et al. He showed that 60% of T1DM patients have ET-1 plasma levels higher than in nondiabetic individuals. [36]

Increase in the TID index is an indicator of subendocardial reversible ischemia due to coronary blood flow disorder as a result of cardiac stress. This ischemia was related to increase of ET-1 plasma levels due to endothelial dysfunction caused by hyperglycemia. This study showed a good positive correlation and statistically significant difference between TID index and ET-1 plasma level with correlation coeficient (r) = 0.7 (P < 0.001). This means that an increase in the ET-1 plasma level will lead to an increase in the TID index. An other study showed the inability of the coronary endothelium to dilate along with perfusion defects in MPS using 201 TI as a response to a physical stress test. The other study showed the severity of clinical manifestations of coronary endothelial dysfunction could depend on the involvement of coronary microvascular. A myocardial perfusion defect on MPS as a result of ischemia could be due to a vasodilation disorder of the coronary microvascular. [36]


   Conclusion Top


There was a significant positive correlation between TID index and ET-1 plasma level in T2DM patients. The higher the ET-1 plasma level, the higher was the TID index.

 
   References Top

1.
Smelley MP, Virnich DE, Williams KA, Ward RP. A hypertensive response to exercise is associated with transient ischemic dilation on myocardial perfusion SPECT imaging. J Nucl Cardiol 2007;14:537-43.  Back to cited text no. 1
    
2.
Kakhki VR. Different aspects of transient ischemic dilation. Iran J Nucl Med 2007;15:30-3.  Back to cited text no. 2
    
3.
Russell RR, Zaret BL. Nuclear cardiology: Present and future. Myocardial perfusion imaging in specific groups: Diabetes mellitus. Curr Probl Cardiol 2006;31:557-629.  Back to cited text no. 3
    
4.
Kakhki VR, Sadeghi R, Zakavi SR. Assessment of transient left ventricular dilation ratio via 2-day dipyridamole Tc-99m sestamibi non-gated myocardial perfusion imaging. J Nucl Cardiol 2007;14:529-36.  Back to cited text no. 4
    
5.
Scholte AJ, Schuijf JD, Kharagjitsingh AV, Dibbets-Schneider P, Stokkel MP, van der Wall EE, et al. Prevalence and predictors of an abnormal stress myocardial perfusion study in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 2009;36:567-75.  Back to cited text no. 5
    
6.
Duarte PS, Smanio PE, Oliveira CA, Martins LR, Mastrocolla LE, Pereira JC. Clinical significance of transient left ventricular dilation assessed during myocardial Tc-99m sestamibi scintigraphy. Arq Bras Cardiol 2003;81:479-82.  Back to cited text no. 6
    
7.
Emmett L, Magee M, Freedman SB, Van der Wall H, Bush V, Trieu J, et al. The role of left ventricular hypertrophy and diabetes in the presence of transient ischemic dilation on the left ventricle on myocardial perfusion SPECT images. J Nucl Med 2005;46:1596-601.  Back to cited text no. 7
    
8.
Emmett L, Van Gaal WJ, Magee M, Bass S, Ali O, Freedman B, et al. Prospective evaluation of the impact of diabetes and left ventricular hypertrophy on the relationship between ischemia and transient ischemic dilation of the left ventricle on single-day adenosine Tc-99m myocardial perfusion imaging. J Nucl Cardiol 2008;15:638-43.  Back to cited text no. 8
    
9.
Halligan WT, Morris PB, Schoepf UJ, Mischen BT, Spearman JV, Spears JR, et al. Transient ischemic dilation of the left ventricle on SPECT: Correlation with findings at coronary CT angiography. J Nucl Med 2014;55:917-22.  Back to cited text no. 9
    
10.
Young LH, Wackers FJ, Chyun DA, Davey JA, Barret EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD Study: A randomized control trial. JAMA 2009;301:1547-55.  Back to cited text no. 10
    
11.
Scholte AJ, Schuijf JD, Kharagjitsingh AV, Dibbets-Schneider P, Stokkel MP, Jukema JW, et al. Different manifestations of coronary artery disease by stress SPECT myocardial perfusion imaging, coronary calcium scoring and multislice CT coronary angiography in asymptomatic patients with type 2 diabetes mellitus. J Nucl Cardiol 2008;15:503-9.  Back to cited text no. 11
    
12.
Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010;11:61-74.  Back to cited text no. 12
    
13.
Michael EW, Noyan G, John FK JR, Joseph AV. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-60.  Back to cited text no. 13
    
14.
Shahab A. Why does diabetes mellitus increase the risk of cardiovascular disease? Acta Med Indones 2006;38:33-41.  Back to cited text no. 14
    
15.
Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002;106:1783-7.  Back to cited text no. 15
    
16.
Murohara T, Lefer AM. Autocrine effects of endothelin-1 on leukocyte-endothelial interaction: Stimulation of endothelin B receptor subtype reduces endothelial adhesiveness via a nitric oxide-dependent mechanism. Blood 1996;88:3894-900.  Back to cited text no. 16
    
17.
Scholte JH. Cardiac imaging for risk stratification in asymptomatic diabetes. J Nucl Cardiol 2006;13:11-8.  Back to cited text no. 17
    
18.
Perfetto F, Tarquini R, Tapparini L, Tarquini B. Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 1998;12:187-92.  Back to cited text no. 18
    
19.
Salerno M, Beller GA. Noninvasive assessment of myocardial perfusion. Circ Cardiovasc Imaging 2009;2:412-24.  Back to cited text no. 19
    
20.
Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 2003;52:1904-9.  Back to cited text no. 20
    
21.
Hardebeck CJ. Transient ischemic dilation. J Am Coll Cardiol 2004;44:211-3.  Back to cited text no. 21
[PUBMED]    
22.
Becker LC. Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia. Circulation 1978;57:1103-10.  Back to cited text no. 22
    
23.
Abidov A, Bax JJ, Hayes SW, Cohen I, Nishina H, Yoda S, et al. Integration of automatically measured transient ischemic dilation ratio into interpretation of adenosine stress myocardial perfusion SPECT for detection of severe and extensive CAD. J Nucl Med 2004;45:1999-2007.  Back to cited text no. 23
    
24.
Heston TF, Sigg DM. Quantifying transient ischemic dilation using gated SPECT. J Nucl Med 2005;46:1990-6.  Back to cited text no. 24
    
25.
McLaughlin MG, Danias PG. Transient ischemic dilation: A powerful diagnostic and prognostic finding of stress myocardial perfusion imaging. J Nucl Cardiol 2002;9:663-7.  Back to cited text no. 25
    
26.
Abidov A, Germano G, Berman DS. Transient ischemic dilation ratio: A universal high-risk diagnostic marker in myocardial perfusion imaging. J Nucl Cardiol 2007;14:497-500.  Back to cited text no. 26
[PUBMED]    
27.
van der Veen BJ, Kuperij N, Stokkel MP. Transient ischemic dilatation ratio derived from myocardial perfusion scintigraphy: What are we looking at? J Nucl Cardiol 2010;17:207-15.  Back to cited text no. 27
    
28.
Hung GU, Lee KW, Chen CP, Lin WY, Yang KT. Relationship of transient ischemic dilation in dipyridamole myocardial perfusion imaging and stress-induced changes of functional parameters evaluated by Tl-201 gated SPECT. J Nucl Cardiol 2005;12:268-75.  Back to cited text no. 28
    
29.
Brodov Y, Guetta V, Di Segni E, Chouraqui P. Clinical predictors of stress-induced transient left ventricular dilatation in patients with nonsignificant coronary disease. J Clin Hypertens (Greenwich) 2010;12:693-7.  Back to cited text no. 29
    
30.
Nacci C, Tarquinio M, Montagnani M. Molecular and clinical aspects of endothelial dysfunction in diabetes. Intern Emerg Med 2009;4:107-16.  Back to cited text no. 30
    
31.
Storey AM, Perry CJ, Petrie JR. Endothelial dysfunction in type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:22-7.  Back to cited text no. 31
    
32.
Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol 2006;5:4.  Back to cited text no. 32
    
33.
Lam HC. Role of endothelin in diabetic vascular complication. Endocrine 2001;14:277-84.  Back to cited text no. 33
    
34.
Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag 2008;4:1061-8.  Back to cited text no. 34
    
35.
Sánchez SS, Aybar MJ, Velarde MS, Prado MM, Carrizo T. Relationship between plasma endothelin-1 and glycemic control in type 2 diabetes mellitus. Horm Metab Res 2001;33:748-51.  Back to cited text no. 35
    
36.
Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 1997;96:3390-5.  Back to cited text no. 36
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1921    
    Printed61    
    Emailed0    
    PDF Downloaded185    
    Comments [Add]    

Recommend this journal